Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes.

Publication

Citation
Zhang X, Cai C, Sui Z, Macielag M, Wang Y, Yan W, Suckow A, Hua H, Bell A, Haug P, Clapper W, Jenkinson C, Gunnet J, Leonard J, Murray WV.: Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes. ACS Med Chem Lett, Volume 8 (9), 2017
Authors
Bell A, Cai C, Clapper W, Gunnet J, Haug P, Hua H, Jenkinson C, Leonard J, Macielag M, Murray WV., Suckow A, Sui Z, Wang Y, Yan W, Zhang X
Journal
ACS Med Chem Lett
Year
2017
PubMed
28947942
Machine-readable
REST APIRDF
Palacky University Olomouc

Palacky University Olomouc

Faculty of Science

Department of Physical Chemistry

tř. 17. listopadu 1192/12

771 46 Olomouc

Czech Republic

How to cite?

Juračka J., Šrejber M., Melíková M., Bazgier V., Berka K.: MolMeDB: Molecules on Membranes Database. Database, Volume 2019, 2019, baz078, https://doi.org/10.1093/database/baz078

Follow us

FacebookGithub

Financial Support

  • MolMeDB interoperability with UniProt and SwissLipids – MEYS Czech-Swiss project ELIXIR-IMPACT 8K0208 (2026–2028)
ELIXIRGAČRUP Olomouc
Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes. | MolMeDB